CAMBRIDGE, Ma. and EXTON, Pa., May 27, 2015 (GLOBE NEWSWIRE) -- Idera Pharmaceuticals, Inc. (Nasdaq:IDRA), a clinical-stage biopharmaceutical company developing toll-like receptor and RNA therapeutics for patients with cancer and rare diseases, today announced that Vincent Milano, Idera's Chief Executive Officer will present a corporate update at the Jefferies 2015 Global Healthcare Conference on Monday, June 1, 2015 at 1:30 p.m. Eastern Time at the Grand Hyatt in New York City.
Mr. Milano will also be presenting at the 9th Annual JMP Securities Healthcare Conference on Wednesday, June 24, 2015 at 12:30 p.m. Eastern Time at the St. Regis Hotel in New York City.
Live audio webcasts of Idera's presentations will be accessible in the Investors and Media section of Idera's website at http://www.iderapharma.com. Archived versions will also be available on the Company's website after the event for 90 days.
About Idera Pharmaceuticals
Idera Pharmaceuticals is a clinical-stage patient focused biopharmaceutical company developing novel therapeutic approaches for the treatment of cancer and rare diseases. Idera's proprietary technology involves creating novel nucleic acid therapeutics. Idera's immunotherapy approach is based on the modulation of Toll-like receptors (TLRs). In addition to its TLR modulation programs, Idera is developing gene silencing oligonucleotides (GSO) technology that it has created to inhibit the production of disease-associated proteins by targeting RNA. To learn more about Idera, visit www.iderapharma.com.
CONTACT: Investor and Media Contact Robert Doody Vice President, Investor Relations and Corporate Communications 484-639-7235 email@example.com